Related Experiment Video
Updated: Jun 22, 2026

Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
Published on: January 12, 2016
Cerebrovascular diseases in HIV-infected patients
Jean-Jacques Monsuez1, Colette Goujon, Benjamin Wyplosz
1AP-HP, Hôpital René Muret, Cardiologie, Policlinique Médicale, Université Paris-13, Faculté de Médecine de Bobigny, SEVRAN 93270, France. jean-jacques.monsuez@rmb.aphp.fr
Insights
Highly active antiretroviral therapy (HAART) in HIV patients increases the risk of premature cerebrovascular disease due to metabolic changes and aging. Long-term vascular prevention strategies are crucial for this growing population.
Area of Science:
- Neurology
- Infectious Diseases
- Cardiovascular Science
Background:
- Cerebrovascular disease (CVD) is a known complication in HIV-infected individuals.
- HIV patients on highly active antiretroviral therapy (HAART) experience increased longevity but face unique vascular risks.
- These risks stem from HAART-induced metabolic disorders and the natural aging process, leading to premature cerebral arteriopathy.
Purpose of the Study:
- To investigate the association between HAART, metabolic changes, aging, and cerebrovascular disease in HIV patients.
- To highlight the emergence of premature atherosclerotic cerebral arteriopathy in this cohort.
- To emphasize the need for long-term vascular prevention strategies.
Main Methods:
- Review of existing studies documenting subclinical atherosclerosis in HIV patients on HAART.
- Assessment of vascular changes using intima-media thickness measurements.
- Ultrasound detection of carotid artery plaques and intracerebral small-vessel disease.
Main Results:
- Subclinical cervical artery atherosclerosis is prevalent in HIV patients on HAART.
- Intima-media thickness and carotid artery plaques correlate with HAART-induced metabolic changes.
- Intracerebral small-vessel disease is also associated with these metabolic alterations.
Conclusions:
- HIV patients on HAART are at increased risk for premature cerebrovascular disease.
- Metabolic changes induced by HAART, combined with aging, contribute significantly to this risk.
- Long-term, proactive vascular prevention is essential for managing HIV-associated cerebrovascular complications.
Abstract:
Cerebrovascular disease (CVD) has early been recognized in HIV-infected patients, including infectious arteritis, inflammatory vasculitis, aneurismal and small-vessel arteriopathy, to which adds now the premature atherosclerotic cerebral arteriopathy associated with the highly active antiretroviral therapy (HAART)-induced metabolic disorders. As a result of the increased life-expectancy associated with HAART, HIV patients grow older and are exposed to the combined vascular risk of antiviral-induced metabolic changes and advancing age. Several studies have documented subclinical cervical artery atherosclerosis, as assessed by intima-media thickness, ultrasound detection of carotid artery plaques and intracerebral small-vessel disease, all being associated with the induced metabolic changes. This suggests that vascular prevention should be performed on a long-term basis.
More Related Videos
Related Concept Videos
Cryptococcal Meningitis
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Dementia l: Introduction
